As of 2026-03-23, the EV/EBITDA ratio of Rapid Dose Therapeutics Corp (DOSE.CN) is -7.15. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. DOSE.CN's latest enterprise value is 18.86 mil CAD. DOSE.CN's TTM EBITDA according to its financial statements is -2.64 mil CAD. Dividing these 2 quantities gives us the above DOSE.CN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 3.0x - 4.5x | 3.8x |
| Forward P/E multiples | 3.0x - 4.5x | 3.8x |
| Fair Price | (0.10) - (0.13) | (0.12) |
| Upside | -207.5% - -238.2% | -222.9% |
| Date | EV/EBITDA |
| 2026-03-17 | -7.41 |
| 2026-03-16 | -7.66 |
| 2026-03-13 | -7.92 |
| 2026-03-12 | -8.18 |
| 2026-03-11 | -8.18 |
| 2026-03-10 | -7.66 |
| 2026-03-09 | -7.92 |
| 2026-03-06 | -8.44 |
| 2026-03-05 | -8.18 |
| 2026-03-04 | -9.21 |
| 2026-03-03 | -9.72 |
| 2026-03-02 | -9.98 |
| 2026-02-27 | -9.98 |
| 2026-02-25 | -9.21 |
| 2026-02-24 | -9.46 |
| 2026-02-23 | -9.46 |
| 2026-02-20 | -9.72 |
| 2026-02-19 | -9.98 |
| 2026-02-18 | -10.49 |
| 2026-02-17 | -10.49 |
| 2026-02-13 | -10.24 |
| 2026-02-12 | -9.21 |
| 2026-02-11 | -9.46 |
| 2026-02-10 | -10.49 |
| 2026-02-05 | -9.72 |
| 2026-02-04 | -9.46 |
| 2026-02-03 | -9.46 |
| 2026-02-02 | -9.46 |
| 2026-01-29 | -9.72 |
| 2026-01-28 | -9.72 |
| 2026-01-26 | -9.46 |
| 2026-01-22 | -9.72 |
| 2026-01-21 | -10.24 |
| 2026-01-20 | -9.98 |
| 2026-01-19 | -9.72 |
| 2026-01-16 | -10.49 |
| 2026-01-15 | -9.46 |
| 2026-01-14 | -9.21 |
| 2026-01-13 | -8.95 |
| 2026-01-12 | -9.72 |
| 2026-01-08 | -9.21 |
| 2026-01-07 | -8.95 |
| 2026-01-06 | -9.72 |
| 2026-01-05 | -9.72 |
| 2026-01-02 | -9.46 |
| 2025-12-31 | -8.95 |
| 2025-12-30 | -8.95 |
| 2025-12-29 | -9.21 |
| 2025-12-24 | -9.46 |
| 2025-12-22 | -8.95 |